Mankind Pharma’s shares dropped 4% following its third-quarter results, which showed a 16% decline in consolidated net profit. The company reported a net profit of Rs 380.2 crore, down from Rs 453.8 crore last year.
However, revenue from operations grew by 24% to Rs 3,230 crore, surpassing the expected Rs 3,180 crore. This growth was fueled by strong performance in the Chronic segment, a recovery in OTC, and the consolidation of Bharat Serums and Vaccines (BSV). Exports saw a significant 121% YoY revenue increase, driven by the expansion of base business and new product launches.
Mankind Pharma’s shares opened at ₹2,560.00, reaching a high of ₹2,564.00 and a low of ₹2,487.15. The stock is currently trading close to its 52-week high of ₹3,054.80, showcasing strong performance. The 52-week low stands at ₹1,901.05. As of 9:55 AM, the shares were trading 4.26% lower at Rs 2,522.70.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
